Use of bisphosphonates to treat severe idiopathic hypercalcaemia in a young Ragdoll cat

Journal of Feline Medicine and Surgery

Volumn 13, Issue 2, 2011, Pages 129-134

  Whitney, Joanna L ^a   Barrs, Vanessa R D ^a   Wilkinson, Margaret R ^b   Briscoe, Katherine A ^a   Beatty, Julia A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; PAMIDRONIC ACID;

ANIMAL; ANIMAL DISEASE; ARTICLE; CASE REPORT; CAT; CAT DISEASE; FEMALE; FOLLOW UP; HOSPITALIZATION; HYPERCALCEMIA; TREATMENT OUTCOME;

ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CAT DISEASES; CATS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HYPERCALCEMIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79251596165     PISSN: 1098612X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfms.2010.09.011     Document Type: Article

References (31)

1. Pope N.M., Kulcinski D.L., Hardwick A., Chang Y.A. New application of silane coupling agents for covalently binding antibodies to glass and cellulose solid supports. Bioconjug Chem 1993, 4:166-171.
2. Bolliger A.P., Graham P.A., Richard V., Rosol T.J., Nachreiner R.F., Refsal K.R. Detection of parathyroid hormone-related protein in cats with humoral hypercalcemia of malignancy. Vet Clin Pathol 2002, 31:3-8.
3. Reiter A.M., Lyon K.F., Nachreiner R.F., Shofer F.S. Evaluation of calciotropic hormones in cats with odontoclastic resorptive lesions. Am J Vet Res 2005, 66:1446-1452.
4. Chew D.J., Schenk P.A. Idiopathic feline hypercalcemia. Kirk's current veterinary therapy XIV 2009, 236-241. Sanders Elsevier, St Louis. J.D. Bonagura, D.C. Twedt (Eds.).
5. Schaer M. Therapeutic approach to electrolyte emergencies. Vet Clin North Am Small Anim Pract 2008, 38:513-533.
6. Midkiff A.M., Chew D.J., Center R.S.A., DiBartola S.P. Idiopathic hypercalcaemia in cats. J Vet Intern Med 2000, 14:619-626.
7. Magoub A., Hirsch P.F., Munson P.L. Calcium-lowering action of glucocorticoids in adrenalectomized-parathyroidectomized rats: specificity and relative potency of natural and synthetic glucocorticoids. Endocrine 1997, 6:279-283.
8. Osborne C.A., Lulich J.P., Thumchai R., et al. Feline urolithiasis. Etiology and pathophysiology. Vet Clin North Am Small Anim Pract 1996, 26:217-232.
9. Chew DJ, Schenck, PA. Idiopathic hypercalcemia - what do I do? Proceeding of the North American Veterinary Conference 2007: 732-4.
10. Behrend E.N. A clinical approach to hypercalcemia. Vet Med 2002, 97:763-772.
11. Milner R.J., Farese J., Henry C.J., Selting K., Fan T.M., de Lorimier L.-P. Bisphosphonates and cancer. J Vet Intern Med 2004, 18:597-604.
12. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996, 18:75-85.
13. Body J.J., Coleman R.E., Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996, 22:265-287.
14. Fan T.M., de Lomerier L.-P., Charney S.C., Hintermeister J.G. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary and secondary bone involvement. J Vet Intern Med 2005, 19:74-80.
15. Rumbeiha W.K., Fitzgerald S.D., Kruger J.M., et al. Use of pamidronate disodium to reduce cholecalciferol-induced toxicosis in dogs. Am J Vet Res 2000, 61:9-13.
16. Hostutler R.A., Chew D.J., Jaeger J.Q., Klein S., Henderson D., DiBartola S.P. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia. J Vet Intern Med 2005, 19:29-33.
17. Fan T.M. Intravenous aminobiphosphonates for managing complications of malignant osteolysis in companion animals. Top Companion Anim Med 2009, 24:151-156.
18. Tanvetyanon T., Stiff P.J. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006, 17:897-907.
19. Tappin S., Rizzo F., Dodkin S., Papasouliotis K., Tasker S., Murphy K. Measurement of ionized calcium in canine blood samples collected in prefilled and self-filled heparinized syringes using the i-STAT point-of-care analyser. Vet Clin Pathol 2008, 37:66-72.
20. Abraham S.C., Cruz-Correa M., Lee L.A., Yardley J.H., Wu T.T. Alendronate-associated oesophageal injury: endoscopic and pathologic features. Mod Pathol 1999, 12:1152-1157.
21. Peter C.P., Handt L.K., Smith S.M. Esophageal irritation due to alendronate sodium tablets possible mechanisms. Dig Dis Sci 1998, 43:1998-2002.
22. German A.J., Cannon M.J., Dye C., et al. Oesophageal strictures in cats associated with doxycycline therapy. J Feline Med Surg 2005, 7:33-41.
23. Beatty J.A., Swift N., Foster D.J., Barrs V.R.D. Suspected clindamycin-associated oesophageal injury in cats: five cases. J Feline Med Surg 2006, 8:412-419.
24. Porras A.G., Holland S.D., Gertz B.J. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999, 36:315-328.
25. Lin J.H., Russell G., Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract 1999, (suppl 101):18-26.
26. Westfall D.S., Twedt D.C., Steyn P.F., Oberhauser E.B., Van Cleave J.W. Evaluation of esophageal transit of tablets and capsules in 30 cats. J Vet Intern Med 2001, 15:467-470.
27. Burr D.B., Allen M.R. Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod Craniofac Res 2009, 12:221-228.
28. Thumbigere-Math V., Sabino M.C., Gopalakrishnan R., et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 2009, 67:1904-1913.
29. Cook AK. Cats and calcium: the causes and consequences of hypercalcemia. Proceedings of the American College of Veterinary Internal Medicine Forum; 2009 June 3-6; Montreal, Canada: 429-31.
30. Chew D. Hypercalcemia in cats Proceedings of the World Small Animal Veterinary Congress, (accessed Nov 21, 2008). http://www.vin.com/VINDBPub/SearchPB/Proceedings/PR05000/PR00123.htm.
31. Patterson C.R., Gunn A. Familial benign hypercalcemia. Lancet 1981, 318:61-63.